



Attorney Docket No.: 4318.224-US

X

RECEIVED

Feb 17 2002

JUL 11 2002

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Box DD
Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Box DD
Commissioner for Patents
Washington, DC 20231

on February 6, 2002.

Julie Tabarovskey
(name of person mailing paper)

J. Tabarovskey
(signature of person mailing paper)

RECEIVED
MAR 11 2002
TC 1700

Copy of References
Original Document

RECEIVED
FEB 28 2002
TC 1700



Attn: Docket No.: 4318.224-US

BEST AVAILABLE COPY

#2
mb
5/15/02
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al. Confirmation No: 7527

Serial No.: 09/902,188 Group Art Unit: 1751

Filed: July 10, 2001 Examiner: To be assigned

For: Amylase Variants

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(c)

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Bisgaard-Frantzen et al., J. Appl. Glycosci., Vol. 46, No. 2, pp. 199-205 (1999)


It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **b for** the mailing date of a first Office action on the merits, or

RECEIVED
FEB 28 2002
TC 1700
RECEIVED
MAR 11 2002
TC 1700

BEST AVAILABLE COPY

b for the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.



Date: February 6, 2002

Respectfully submitted,


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123

ORIGINAL COPY
COPY OF PAPER

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

RECEIVED
FEB 28 2002
TC 1700

RECEIVED
MAR 11 2002
TC 1700